查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1579428

Batten 疾病市場：按產品類型、疾病類型、給藥途徑和最終用戶 - 2025-2030 年全球預測

Batten Disease Market by Product, Type of Disease, Route of Administration, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年巴頓病市場價值為5,489萬美元，預計2024年將達5,761萬美元，複合年成長率為5.18%，到2030年將達7,819萬美元。

巴頓病是一種罕見且致命的體染色體隱性神經退化性疾病，主要影響兒童，是由基因突變引起的，這些突變會損害細胞健康所需的某些酶的功能。了解 KEYWORD 的必要性在於其使人衰弱的性質和缺乏有效的治療方法，這促使研究人員努力開發新的治療策略。應用集中在基因療法、酵素替代療法和小分子藥物。最終用途範圍從醫院和診斷中心到專門治療神經系統疾病的專門治療設施。由於意識的提高、基因研究的進步以及罕見疾病研究資金的增加，該市場正在不斷成長。影響成長的關鍵因素包括診斷和治療的技術進步以及對個人化醫療方法的日益重視。開發新療法和改進診斷工具存在潛在的商機，公司應該投資研發來開拓這些領域。與學術機構的合作和參與臨床試驗可以加速進展。然而，這個市場面臨局限性，包括研發成本高、對疾病病理生理學了解不足以及與孤兒藥相關的監管挑戰。患者數量少也是一個重大挑戰，可能會阻礙大規模臨床試驗和商業化。業務成長的創新領域包括使用 CRISPR 技術進行基因編輯、基於先進生物標記的診斷，以及使用人工智慧進行藥物發現和患者分層。此外，基因治療和個人化醫療是有前景的研究和創新領域。市場的性質是專業化的，並由生物技術的進步所驅動。因此，公司必須注重以患者為中心的方法和策略夥伴關係關係，以最大限度地提高潛在利益。策略研究可能包括透過倡導團體來提高意識、參與合作研究以及考慮政府對孤兒藥開發的激勵措施，以成功駕馭這個利基市場。

主要市場統計
基準年[2023] 5489萬美元
預測年份 [2024] 5761萬美元
預測年份 [2030] 7819萬美元
複合年成長率（%） 5.18%

市場動態：針對快速發展的巴頓病市場所揭示的關鍵市場見解

供需的動態交互作用正在改變巴頓病市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 提高對巴頓氏症的認知和診斷
    • 加大對罕見疾病研究的投入
    • 改善醫療基礎設施和獲取機會
  • 市場限制因素
    • 有限的臨床試驗資料和監管挑戰
  • 市場機會
    • 創新治療藥物的開發
    • 基因組研究和個人化醫療的進展
  • 市場挑戰
    • 疾病的複雜性和治療方法的發展

波特五力策略工具駕馭巴頓病市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解對 Batten 疾病市場的外部影響

外部宏觀環境因素在塑造巴頓病市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解巴頓氏症市場的競爭狀況

對巴頓病市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣巴頓病市場供應商績效評估

FPNV 定位矩陣是評估巴頓病市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了巴頓病市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對巴頓病市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高對巴頓氏症的認知和診斷
      • 加大對罕見疾病研究的投入
      • 改善醫療基礎設施和獲取機會
    • 抑制因素
      • 有限的臨床試驗資料和監管挑戰
    • 機會
      • 開發創新治療方法
      • 基因組研究和個人化醫療的進展
    • 任務
      • 疾病的複雜性和治療方法的發展
  • 市場區隔分析
    • 產品：cerliponase alpha 在治療上日益重要
    • 最終用戶：醫院環境中的多種應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章巴頓病市場：依產品

  • 藥物
    • 絲脂酶α
    • 左乙拉西坦
    • 丙戊酸
  • 基因治療

第 7 章 依疾病類型分類的巴滕疾病市場

  • 成人神經元蠟質脂褐質沉著症
  • 嬰兒神經蠟質脂褐質沉著症
  • 幼年神經元蠟質脂褐質沉著症
  • 晚期嬰兒神經蠟質脂褐質沉著症

第8章巴頓疾病市場：依給藥途徑

  • 靜脈
  • 腦室內
  • 口服

第9章巴頓疾病市場：按最終用戶

  • 家庭護理設置
  • 醫院
  • 調查機構
  • 專科診所

第10章美洲巴頓病市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太巴頓病市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲巴頓病市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Latus Bio, Inc. 已獲得 5,400 萬美元的 A 輪資金籌措，旨在透過精準標靶化和更安全的管理徹底改變中樞神經系統基因治療。
    • 羅徹斯特大學醫學中心正在加強對抗巴頓病，並獲得 NINDS 的 570 萬美元資金來加速基因治療試驗。
  • 戰略分析和建議

公司名單

  • Abeona Therapeutics Inc.
  • Alexion Pharmaceuticals Inc.
  • Amicus Therapeutics
  • BioMarin Pharmaceutical Inc.
  • Denali Therapeutics
  • Neurogene Inc.
  • Novartis AG
  • Orchard Therapeutics
  • Passage Bio, Inc.
  • Regenxbio Inc.
  • Teva Pharmaceuticals Industries Ltd.
Product Code: MRR-B53D3ECDD928

The Batten Disease Market was valued at USD 54.89 million in 2023, expected to reach USD 57.61 million in 2024, and is projected to grow at a CAGR of 5.18%, to USD 78.19 million by 2030.

Batten Disease, a rare and fatal autosomal recessive neurodegenerative disorder, predominantly affects children and is caused by genetic mutations that impair the function of certain enzymes necessary for cell health. The necessity of understanding Batten Disease lies in its debilitating nature and the lack of effective treatment options, driving research efforts to develop novel therapeutic strategies. Application revolves around gene therapy, enzyme replacement therapy, and small molecule drugs. The end-use scope spans from hospitals and diagnostic centers to specialized treatment facilities focusing on neurological disorders. The market is witnessing growth due to increasing awareness, advances in genetic research, and rising funding for orphan disease research. Key factors influencing growth include technological advancements in diagnostics and therapeutics, coupled with a growing emphasis on personalized medicine approaches. Potential opportunities exist in the development of novel therapeutics and improved diagnostic tools; thus, companies should invest in R&D to explore these areas. Collaborative efforts with academic institutions and participation in clinical trials can accelerate advancements. However, the market faces limitations such as high R&D costs, limited understanding of the disease's pathophysiology, and regulatory challenges associated with orphan drugs. Another significant challenge is the small patient population, which can impede large-scale clinical trials and commercialization. Innovative areas for business growth include using CRISPR technology for gene editing, advanced biomarker-based diagnostics, and leveraging artificial intelligence for drug discovery and patient stratification. Moreover, gene therapy and personalized medicine represent promising arenas for research and innovation. The nature of the market is specialized and driven by advancements in biotechnology; hence, companies need to focus on patient-centric approaches and strategic partnerships to maximize potential benefits. Strategic recommendations include amplifying awareness through advocacy groups, engaging in collaborative research, and exploring government incentives for orphan drug development to successfully navigate this niche market.

KEY MARKET STATISTICS
Base Year [2023] USD 54.89 million
Estimated Year [2024] USD 57.61 million
Forecast Year [2030] USD 78.19 million
CAGR (%) 5.18%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Batten Disease Market

The Batten Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased awareness and diagnosis of batten disease
    • Rising investment in rare disease research
    • Improvement in healthcare infrastructure and access
  • Market Restraints
    • Limited clinical trial data and regulatory challenges
  • Market Opportunities
    • Development of innovative therapeutics
    • Advancements in genomic research and personalized medicine
  • Market Challenges
    • Complexity of disease and treatment development

Porter's Five Forces: A Strategic Tool for Navigating the Batten Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Batten Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Batten Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Batten Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Batten Disease Market

A detailed market share analysis in the Batten Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Batten Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Batten Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Batten Disease Market

A strategic analysis of the Batten Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Batten Disease Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alexion Pharmaceuticals Inc., Amicus Therapeutics, BioMarin Pharmaceutical Inc., Denali Therapeutics, Neurogene Inc., Novartis AG, Orchard Therapeutics, Passage Bio, Inc., Regenxbio Inc., and Teva Pharmaceuticals Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Batten Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Drugs and Gene Therapy. The Drugs is further studied across Cerliponase Alfa, Levetiracetam, and Valproic Acid.
  • Based on Type of Disease, market is studied across Adult Neuronal Ceroid Lipofuscinosis, Infantile Neuronal Ceroid Lipofuscinosis, Juvenile Neuronal Ceroid Lipofuscinosis, and Late Infantile Neuronal Ceroid Lipofuscinosis.
  • Based on Route of Administration, market is studied across Intravenous, Intraventricular, and Oral.
  • Based on End-User, market is studied across Homecare Settings, Hospitals, Research Institutions, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased awareness and diagnosis of batten disease
      • 5.1.1.2. Rising investment in rare disease research
      • 5.1.1.3. Improvement in healthcare infrastructure and access
    • 5.1.2. Restraints
      • 5.1.2.1. Limited clinical trial data and regulatory challenges
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of innovative therapeutics
      • 5.1.3.2. Advancements in genomic research and personalized medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of disease and treatment development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising significance of cerliponase alfa in treatment
    • 5.2.2. End-User: Diverse scope of applications in hospital settings
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Batten Disease Market, by Product

  • 6.1. Introduction
  • 6.2. Drugs
    • 6.2.1. Cerliponase Alfa
    • 6.2.2. Levetiracetam
    • 6.2.3. Valproic Acid
  • 6.3. Gene Therapy

7. Batten Disease Market, by Type of Disease

  • 7.1. Introduction
  • 7.2. Adult Neuronal Ceroid Lipofuscinosis
  • 7.3. Infantile Neuronal Ceroid Lipofuscinosis
  • 7.4. Juvenile Neuronal Ceroid Lipofuscinosis
  • 7.5. Late Infantile Neuronal Ceroid Lipofuscinosis

8. Batten Disease Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Intraventricular
  • 8.4. Oral

9. Batten Disease Market, by End-User

  • 9.1. Introduction
  • 9.2. Homecare Settings
  • 9.3. Hospitals
  • 9.4. Research Institutions
  • 9.5. Specialty Clinics

10. Americas Batten Disease Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Batten Disease Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Batten Disease Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Latus Bio, Inc. secures USD 54 million series a funding to revolutionize CNS gene therapy with precision targeting and safer dosing
    • 13.3.2. University of Rochester medical center bolsters efforts in battling batten disease with USD 5.7 million NINDS funding to accelerate gene therapy trials
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Alexion Pharmaceuticals Inc.
  • 3. Amicus Therapeutics
  • 4. BioMarin Pharmaceutical Inc.
  • 5. Denali Therapeutics
  • 6. Neurogene Inc.
  • 7. Novartis AG
  • 8. Orchard Therapeutics
  • 9. Passage Bio, Inc.
  • 10. Regenxbio Inc.
  • 11. Teva Pharmaceuticals Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BATTEN DISEASE MARKET RESEARCH PROCESS
  • FIGURE 2. BATTEN DISEASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BATTEN DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BATTEN DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BATTEN DISEASE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BATTEN DISEASE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BATTEN DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BATTEN DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BATTEN DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BATTEN DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BATTEN DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BATTEN DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BATTEN DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BATTEN DISEASE MARKET DYNAMICS
  • TABLE 7. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BATTEN DISEASE MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BATTEN DISEASE MARKET SIZE, BY CERLIPONASE ALFA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BATTEN DISEASE MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BATTEN DISEASE MARKET SIZE, BY VALPROIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BATTEN DISEASE MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BATTEN DISEASE MARKET SIZE, BY ADULT NEURONAL CEROID LIPOFUSCINOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BATTEN DISEASE MARKET SIZE, BY INFANTILE NEURONAL CEROID LIPOFUSCINOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BATTEN DISEASE MARKET SIZE, BY JUVENILE NEURONAL CEROID LIPOFUSCINOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BATTEN DISEASE MARKET SIZE, BY LATE INFANTILE NEURONAL CEROID LIPOFUSCINOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BATTEN DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BATTEN DISEASE MARKET SIZE, BY INTRAVENTRICULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BATTEN DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BATTEN DISEASE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BATTEN DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BATTEN DISEASE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BATTEN DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES BATTEN DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. BATTEN DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. BATTEN DISEASE MARKET, FPNV POSITIONING MATRIX, 2023